Myrophine
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 7,8-didehydro-4,5α-epoxy-17-methyl-3-(phenylmethoxy)-morphinan-6-ol tetradecanoate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Schedule I (US) |
| Identifiers | |
| CAS number | 467-18-5 |
| ATC code | None |
| PubChem | CID 635600 |
| UNII | 417TUP54OL  |
| Synonyms | Myristylbenzylmorphine |
| Chemical data | |
| Formula | C38H51NO4 |
| Mol. mass | 585.82 g/mol |
 (what is this?) (verify) |
|
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine.
Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is a Schedule I drug in the USA and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308.
